Cadrenal Therapeutics completed a private placement with an institutional investor, securing approximately $3.0 million in gross proceeds. The financing comprised 960,000 pre-funded warrants and accompanying Series C-1 and Series C-2 common warrants sold at a combined $3.1249 per pre-funded warrant and warrants, with exercise prices of $0.0001 and $3.00, respectively. The company plans to use the funds for working capital. In a concurrent Registration Rights Agreement, Cadrenal committed to file a resale registration within 15 days and achieve effectiveness within 45 days (or 75 days if fully reviewed), with liquidated damages of 1% per 30 days for certain delays, capped at 6%.
Agreement 1: Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants
- Agreement type: Securities Purchase Agreement for private placement of warrants
- Counterparty: Institutional investor
- Signed / Effective: Jun 30 2026 / Jul 01 2026
- Duration / Termination: N/A
- Reason: Raise working capital and strengthen liquidity
Agreement 2: Cadrenal Therapeutics Grants Resale Registration Rights to Investor Following Warrants Financing
- Agreement type: Registration Rights Agreement for resale of warrant shares
- Counterparty: Institutional investor
- Signed / Effective: Jun 30 2026 / Jun 30 2026
- Duration / Termination: Until all registered shares are sold or freely tradable
- Reason: Provide resale liquidity to investor
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.